Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2008

View Archived Issues

Evidence of activity with AP-5346 seen in potentially platinum-sensitive ovarian cancer

New anticancer agents reported in recent patent literature

TRI-1144 well tolerated in healthy subjects

Flupirtine mechanism of action may be useful in treating overactive bladder

Pacgen enters into a letter of intent with Medigen

NeuroSearch initiates dosing in HART study of ACR-16 in Huntington's disease

BioCryst reports results from phase II trial of peramivir in hospitalized influenza patients

Evotec reports results from phase I safety study of EVT-302

Minster announces results from phase II trial of tonabersat for migraine with aura

New agents for neuropsychiatric disorders reported in recent Actelion and Abbott patents

Recent patent reports novel agents for inflammatory and autoimmune diseases

Medivir reviews significant events for third quarter 2008

Elan updates R&D progress for third quarter 2008

Pain associated with IBS reduced after treatment with GTP-010 in a phase II study

Phase II results with amadacycline in cSSSI support advancement into phase III

Galenea and Organix enter exclusive license agreement for 5-HT2C agonists

OraSure files for FDA approval of OraQuick rapid HCV test

PharmAthene initiates phase I trial of nerve agent bioscavenger Protexia

Bevirimat achieves plasma levels in target range for virologic reduction in HIV

Protectan CBLB-612 reduces myelosuppression in mouse model of chemotherapy

Questcor evaluates Acthar as potential new treatment for nephrotic syndrome

Phase III international trial initiated for IPI-504 in patients with gastrointestinal stromal tumors

Aphios receives phase I SBIR grant from NIDA to develop dronabinol for marijuana addiction

FDA grants clearance to Ikonisys' oncoFISH her-2 breast cancer test

VasoGenix reports results from preclinical testing of CGRP for heart failure

Rasilez HCT receives Swiss approval for the treatment of high blood pressure

UCB's Vimpat approved by FDA as adjunctive therapy for seizures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...